Stockscreener 앱 받기
32.38
0.25%
0.08
시간 외 거래:
32.30
-0.08
-0.25%
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
Will Viking Therapeutics’ New CCO Reframe VKTX’s Obesity Strategy Amid Intensifying GLP-1 Competition? - simplywall.st
Viking Therapeutics: A Tale of Strategic Hiring and Insider Sales - AD HOC NEWS
Viking Therapeutics Hires Neil Aubuchon as Chief Commercial Officer - Contract Pharma
Viking Therapeutics appoints Neil Aubuchon as chief commercial officer By Investing.com - Investing.com Nigeria
Viking Therapeutics appoints Neil Aubuchon as chief commercial officer - Investing.com India
Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer - PR Newswire
Viking Therapeutics (VKTX) Valuation Check After Recent Share Price Weakness - Yahoo Finance
Viking Therapeutics Faces Scrutiny Amid Insider Sales and Key Industry Event - AD HOC NEWS
Here's What $100 Invested in Viking Therapeutics a Decade Ago Would Amount to Now - Bitget
Examining the Latest Short Interest in Viking Therapeutics Inc - Bitget
Looking Into Viking Therapeutics Inc's Recent Short Interest - Benzinga
Viking Therapeutics Stock Suffers Worst Day In Over 4 Months As Top Execs Dump Shares — Novo’s $149 Wegovy Move Looms - Stocktwits
Insider Sales and Market Competition Weigh on Viking Therapeutics Shares - AD HOC NEWS
Viking Therapeutics Insider Sold Shares Worth $7,692,121, According to a Recent SEC Filing - MarketScreener
Viking Therapeutics Insider Sold Shares Worth $1,896,969, According to a Recent SEC Filing - MarketScreener
Leadership Stock Sales Cast Shadow Over Viking Therapeutics’ Prospects - AD HOC NEWS
What drives Viking Therapeutics Inc 1VT stock pricePrice Action Analysis & Low Risk Wealth Building - earlytimes.in
Viking Therapeutics stock suffers worst day in over 4 months as top execs dump shares — Novo’s $149 Wegovy move looms - MSN
Insider Sell Alert: Matthew Foehr Sells 16,000 Shares of Viking Therapeutics Inc (VKTX) - GuruFocus
Insider Selling: Viking Therapeutics (NASDAQ:VKTX) CEO Sells 233,409 Shares of Stock - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) CFO Sells $1,897,046.90 in Stock - MarketBeat
Marianna Mancini Sells 57,661 Shares of Viking Therapeutics (NASDAQ:VKTX) Stock - MarketBeat
Viking Therapeutics CEO Lian sells $7.69m in shares By Investing.com - Investing.com Nigeria
Viking therapeutics COO Mancini sells $1.9 million in stock By Investing.com - Investing.com Nigeria
Viking Therapeutics CEO Lian sells $7.69m in shares - Investing.com
Viking therapeutics COO Mancini sells $1.9 million in stock - Investing.com
Viking Therapeutics director Foehr sells $561,694 in shares - Investing.com
Viking therapeutics CFO Zante sells $1.89m in shares By Investing.com - Investing.com UK
Viking Therapeutics director Foehr sells $561,694 in shares By Investing.com - Investing.com UK
A Look At Viking Therapeutics (VKTX) Valuation As Long Term Gains Contrast Recent Losses - simplywall.st
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note - sharewise.com
Viking Therapeutics (NASDAQ:VKTX) Trading Down 6.1%What's Next? - MarketBeat
Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing - TechStock²
$VKTX stock is down 10% today. Here's what we see in our data. - Quiver Quantitative
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today - AOL.com
Viking Therapeutics 2026: How Brian Lian Built a $4B Metabolic Fortress - CEO Today
How A Wall Street Analyst Started A $4 Billion Obesity Drug Company - Forbes
Viking Therapeutics Shares Consolidate as Investors Await Clinical Catalyst - AD HOC NEWS
Viking Therapeutics: The Obesity Drugs Gold Rush Is Far From Over (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics: A Tale of Clinical Momentum and Financial Strain - AD HOC NEWS
Could Viking Therapeutics Become the Next Eli Lilly? - MSN
Here's How VKTX's Obesity Drug Is Moving Quickly Through Phase III - sharewise.com
Viking Therapeutics Accelerates Toward Pivotal Obesity Drug Data - AD HOC NEWS
Viking Therapeutics, Inc. $VKTX Shares Sold by Voya Investment Management LLC - MarketBeat
Viking Therapeutics Achieves Key Clinical Milestone Ahead of Schedule - AD HOC NEWS
Viking Therapeutics: A Wide-Open Oral GLP-1 Market (NASDAQ:VKTX) - Seeking Alpha
2 beaten-down stocks that could bounce back in 2026 - MSN
2 Beaten-Down Stocks That Could Bounce Back in 2026 - Finviz
The End of Shots? 5 Biotech Stocks Rethinking Diabetes - ADVFN
Viking Therapeutics: A High-Stakes Investment at a Critical Juncture - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - sharewise.com
Viking Therapeutics Shares Face Mounting Pressure - AD HOC NEWS
Insider Selling and Clinical Progress Shape Viking Therapeutics’ Stock Trajectory - AD HOC NEWS
Harbor Capital Advisors Inc. Trims Stock Holdings in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics: Investors Eye Pivotal Phase 3 Catalyst - AD HOC NEWS
Viking Therapeutics' Swing Trade Potential EmergesCompetition/Dilution Risks Remain (NASDAQ:VKTX) - Seeking Alpha
Price Action: Is Viking Therapeutics Inc. stock a good choice for value investorsMarket Volume Report & Real-Time Sentiment Analysis - moha.gov.vn
Viking Therapeutics, Inc. (VKTX) beats stock market upswing: What investors need to know - MSN
Market Moves: Is Viking Therapeutics Inc. stock a good choice for value investorsJuly 2025 Market Mood & Growth Focused Entry Reports - moha.gov.vn
Why This Beaten-Down GLP-1 Stock Could Be a Steal - AOL.com
Here's How Much $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today - Sahm
28.63%
자본화:
|
볼륨(24시간):